Fri, Dec 26, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Opportunities remain for investors to access high quality listed hedge funds at discount to NAV

Wednesday, June 16, 2010

Benedicte Gravrand, Opalesque London:

The listed hedge fund sector was destabilised at the end of 2008 but is getting back on its feet now, although there are still discounts for investors to take advantage of. And some see the sector veering towards the niche market, or towards becoming large, more reliable entities.

RBS: Key is to access quality listed hedge funds at discount NAV There are around 86 closed-end funds listed on the London Stock Exchange with combined assets of £2,479m (US$3,672m) vs. a combined market cap of £2,991m ($4,431m).

The listed hedge fund sector currently has 23 funds of hedge funds (FoHFs) with an aggregate TNA of £4,197m ($6,217m) and an aggregate market cap of £3,351m ($4,964m). It also has 11 single manager hedge funds, with TNA of £3,745m ($5,548m) and cap of £3,515m ($5,207m).

“Clearly there is a shortfall here,” said Mark James, executive director at the RBS (Royal Bank of Scotland) Investment Funds Team in a seminar organised by Peregrine in London last month. “This is a key attraction for investors looking into hedge funds.”

The listed FoHFs include Absolute Invest, Absolute Return Trust, Acencia Debt Strategies, Aida Fund, Alternative Investment, Altin, Blackrock Absolute Return, Castle Alternative, CMA Global Hedge, Dexion, FRM, Goldman Sachs Dynamic Opps, Gottex Market Neutral Trust, In......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its